Townsend Adam J. 4
4 · Apellis Pharmaceuticals, Inc. · Filed Apr 5, 2023
Insider Transaction Report
Form 4
Townsend Adam J.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-04-03$74.05/sh−5,000$370,250→ 75,995 total - Exercise/Conversion
Common Stock
2023-04-03$15.09/sh+5,000$75,450→ 80,995 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-04-03−5,000→ 287,500 totalExercise: $15.09Exp: 2028-11-15→ Common Stock (5,000 underlying)
Footnotes (2)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.